Artivion, Inc. (NYSE:AORT – Get Free Report) SVP Jean F. Holloway sold 472 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $25.29, for a total value of $11,936.88. Following the completion of the sale, the senior vice president now directly owns 172,743 shares in the company, valued at approximately $4,368,670.47. The trade was a 0.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.
Artivion Price Performance
Shares of NYSE AORT opened at $24.78 on Friday. The firm has a 50-day simple moving average of $29.23 and a 200-day simple moving average of $27.80. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -1,239.05 and a beta of 1.79. Artivion, Inc. has a 52 week low of $19.11 and a 52 week high of $32.33.
Artivion (NYSE:AORT – Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The business had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. On average, equities analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.
Institutional Trading of Artivion
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on AORT shares. Stifel Nicolaus dropped their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. JMP Securities reiterated a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a research report on Tuesday, December 10th. Oppenheimer upped their price target on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Finally, Needham & Company LLC lowered their price objective on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artivion presently has an average rating of “Buy” and an average target price of $31.40.
View Our Latest Stock Analysis on AORT
About Artivion
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Featured Stories
- Five stocks we like better than Artivion
- Overbought Stocks Explained: Should You Trade Them?
- 4 EV Stocks Facing Uncertainty—Which Ones Will Survive?
- About the Markup Calculator
- These 3 Big Banks Are Set to Gain as Consumers Stash More Cash
- How to Read Stock Charts for Beginners
- Wall Street Says Chipotle Has 30% Upside—Should You Bite?
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.